What is Karyopharm Therapeutics Inc.'s Shariah compliance score?

Karyopharm Therapeutics Inc. (KPTI) has a Shariah compliance score of 0/100 (Grade: F, Non-Compliant). AAOIFI Standard No. 21 requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30%, (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%.

Does Karyopharm Therapeutics Inc. pass AAOIFI screening?

Karyopharm Therapeutics Inc. (KPTI) does not pass AAOIFI Shariah screening. AAOIFI Standard No. 21 requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30%, (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. KPTI's debt-to-market-cap is 544.3%.

How much purification is needed for Karyopharm Therapeutics Inc.?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the percentage and amount for Karyopharm Therapeutics Inc. (KPTI) using the latest financial data.

Where can I screen Karyopharm Therapeutics Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Karyopharm Therapeutics Inc. (KPTI) and 8,200+ securities. US-listed stocks and ETFs are screened under AAOIFI Standard No. 21. Bursa Malaysia securities carry the Securities Commission Malaysia's official status. Coins are screened separately, under published scholarly opinion. The verdict is free, with no credit card or signup required for basic screening. The compliance grade, score, and debt ratio are free too; the full ratio breakdown is part of Pro.

KPTINot HalalF

Unlock full report, free

KPTI: Is Karyopharm Therapeutics Inc. Halal?

Karyopharm Therapeutics Inc.

NASDAQHealthcareUS

$1.62

Market Cap: 36.7M

Compliance Status

Not Halal

Screened on Sep 24, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Karyopharm Therapeutics Inc. (KPTI) halal? Not Halal. Based on AAOIFI screening, Karyopharm Therapeutics Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Karyopharm Therapeutics Inc. (KPTI) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 24, 2026. Source: https://halalscreener.app/en/stock/KPTI

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Over the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

544.3% of 30.0% limit

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding KPTI

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Get an email if KPTI's halal status changes

We re-screen Karyopharm Therapeutics Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

Interest-bearing debt is 544.3% of market cap, over the 30% AAOIFI limit.
Interest-bearing deposits are over the 30% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 24, 2026

See which ratio caused the failure.

See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.

Free for 7 days. Cancel anytime.

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

See why KPTI is rated Not Halal with institutional-grade analysis

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

BLTEA+

Belite Bio, Inc

$167.33

0001.KLA+

Supercomnet Technologies Bhd

$0.50

+0.01%

0002.KLA+

Kotra Industries Bhd

$3.85

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.43

-0.01%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.35

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track KPTI and 8,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Karyopharm Therapeutics Inc. (KPTI) halal to invest in?

Karyopharm Therapeutics Inc. (KPTI) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Karyopharm Therapeutics Inc. get a F compliance rating?

Karyopharm Therapeutics Inc. (KPTI) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 544.3% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Karyopharm Therapeutics Inc.'s Shariah verdict?

Karyopharm Therapeutics Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Karyopharm Therapeutics Inc. re-screened for Shariah compliance?

Karyopharm Therapeutics Inc. (KPTI) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 24, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.